Xtant Medical (NYSEAMERICAN:XTNT) Price Target Cut to $1.50 by Analysts at BTIG Research

Xtant Medical (NYSEAMERICAN:XTNT) had its price target reduced by research analysts at BTIG Research from $2.00 to $1.50 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the medical device company’s stock. BTIG Research’s target price would suggest a potential upside of 86.57% from the company’s current price.

Xtant Medical Stock Up 5.7%

Shares of NYSEAMERICAN:XTNT traded up $0.04 during midday trading on Tuesday, reaching $0.80. The company’s stock had a trading volume of 282,007 shares, compared to its average volume of 150,020. The company has a quick ratio of 1.16, a current ratio of 2.47 and a debt-to-equity ratio of 0.46. The firm has a 50 day moving average of $0.71 and a 200-day moving average of $0.66. The firm has a market capitalization of $112.56 million, a P/E ratio of -20.18 and a beta of -0.22. Xtant Medical has a 12-month low of $0.33 and a 12-month high of $0.95.

Hedge Funds Weigh In On Xtant Medical

Several large investors have recently made changes to their positions in the business. Jane Street Group LLC bought a new stake in shares of Xtant Medical in the 2nd quarter worth approximately $26,000. Mink Brook Asset Management LLC boosted its holdings in Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after acquiring an additional 60,997 shares in the last quarter. Crescent Grove Advisors LLC grew its stake in shares of Xtant Medical by 94.3% in the second quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock worth $304,000 after acquiring an additional 200,000 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Xtant Medical by 4.6% in the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after acquiring an additional 104,159 shares during the last quarter. Finally, AWM Investment Company Inc. bought a new position in shares of Xtant Medical during the second quarter valued at $4,875,000. 69.33% of the stock is currently owned by hedge funds and other institutional investors.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.